Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854561 | 0.86 | ALDH1A1 (0.41) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL855653 | 0.79 | ALOX15 (0.37) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL30523205 | 0.79 | ALOX15 (0.37) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL27801935 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL855592 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL9284604 | 0.76 | TYMS (0.47) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL855562 | 0.75 | ALDH1A1 (0.52) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL4924942 | 0.74 | ALDH1A1 (0.41) | ALDH1A1TSHRTYMSALOX15TDP1 | |
| SCHEMBL13991787 | 0.73 | TSHR (0.39) | ALDH1A1TSHR | |
| SCHEMBL79833 | 0.73 | ALOX15 (0.48) | ALDH1A1TSHRTYMSALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305082-A1 | 1,4-Bis-N-Oxide-5,8- Dihydroxyanthracenedione Compounds and the Use Thereof | NOVACEA, INC. | 2008-12-11 | — | — | US | disclosed |
| WO-2008103320-A1 | METHODS OF TREATING OPHTHALMIC DISORDERS WITH ANTHRAQUINONES | NOVACEA, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2006031719-A2 | 1,4-BIS-N-OXIDE-5,8-DIHYDROXYANTHRACENEDIONE COMPOUNDS AND THE USE THEREOF | NOVACEA, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305082-A1 | 1,4-Bis-N-Oxide-5,8- Dihydroxyanthracenedione Compounds and the Use Thereof | RB1, BRCA1, CCNA1 | ALDH1A1 103/4885TSHR 2635/4885TYMS 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.